Skip to content
Enrolling by invitationN/A

Long Term Follow Up KET-PD

NCT06164756 · Yale University

Closed to entry
Status
Not accepting participants
Not applicable
Phase
40
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Long-Term Change in Depression Severity

    Measured over 3 Months and 6 Months

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

40 Years to 80 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Eligibility is determined in the ongoing parent clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).

Where

1 study site

FacilityCityRegionCountry
Yale New Haven HospitalNew HavenConnecticutUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06164756 on ClinicalTrials.gov →

Last updated in the registry 2025-07-11. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits